Literature DB >> 20643517

How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?

Shu-Zhen Lai1, Wen-Fei Li, Lei Chen, Wei Luo, Yuan-Yuan Chen, Li-Zhi Liu, Ying Sun, Ai-Hua Lin, Meng-Zhong Liu, Jun Ma.   

Abstract

PURPOSE: To compare the results of intensity-modulated radiotherapy (IMRT) with those of two-dimensional conventional radiotherapy (2D-CRT) in the treatment of patients with nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: A retrospective review of data from 1,276 patients with biopsy-proven, nonmetastatic NPC was performed. All patients had undergone magnetic resonance imaging and were staged according to the sixth edition of the American Joint Committee on Cancer staging criteria. Radiotherapy was the primary treatment for all patients.
RESULTS: Of the 1,276 patients, 512 were treated with IMRT and 764 with 2D-CRT. The 5-year actuarial local relapse-free survival (LRFS), the nodal relapse-free survival (NRFS), the distant metastasis-free survival (DMFS), and the disease-free survival (DFS) rates were 92.7%, 97.0%, 84.0%, and 75.9%, respectively, for the IMRT group, and 86.8%, 95.5%, 82.6%, and 71.4%, respectively, for the 2D-CRT group. In stage T1 patients, improvement of LRFS in the IMRT group was even significantly higher than in the 2D-CRT group (100% vs. 94.4%; p = 0.016). A trend of improvement of DFS was observed in the IMRT group compared with the 2D-CRT group but without reaching statistical significance. NRFS and DMFS rates were similar in the two groups.
CONCLUSIONS: A greater improvement of treatment results with IMRT than with 2D-CRT was demonstrated primarily by achieving a higher local tumor control rate in NPC patients, especially in the early T stage patients. The goal of better control of both local failure in advanced, nonmetastatic NPC patients and of distant failure should be addressed in future studies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643517     DOI: 10.1016/j.ijrobp.2010.03.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  293 in total

1.  Intensity-modulated radiotherapy for sinonasal teratocarcinosarcoma.

Authors:  Gang Peng; Yang Ke; Tao Wang; Yiming Feng; Yuehua Li; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

2.  Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma. A follow-up study.

Authors:  X Rong; Y Tang; M Chen; K Lu; Y Peng
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

3.  MRI-detected skull-base invasion: prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma.

Authors:  Yi-Kan Cheng; Li-Zhi Liu; Ning Jiang; Dan Yue; Ling-Long Tang; Fan Zhang; Li Lin; Xu Liu; Lei Chen; Jun Ma
Journal:  Strahlenther Onkol       Date:  2014-04-25       Impact factor: 3.621

4.  Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma.

Authors:  Rou Jiang; Zhong-Han Yang; Dong-Hua Luo; Ling Guo; Rui Sun; Qiu-Yan Chen; Pei-Yu Huang; Fang Qiu; Xiong Zou; Ka-Jia Cao; Hai-Qiang Mai; Xiang Guo; Chao-Nan Qian; Ming-Huang Hong; Ming-Yuan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 5.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

Review 6.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

7.  Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Authors:  Feng Jiang; Wei Hu; Bicheng Zhang; Jing Xu; Yongjie Shui; Xiaofeng Zhou; Xiaoqiu Ren; Xiaozhong Chen; Li Shen; Qichun Wei
Journal:  Biomed Rep       Date:  2016-09-12

8.  ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.

Authors:  Ya-Jing Zhuang; Zhi-Wei Liao; Hong-Wei Yu; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Xiao-Dan Lin; Tong-Chong Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 9.  IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06).

Authors:  Sung Ho Moon; Kwan Ho Cho; Chang-Geol Lee; Ki Chang Keum; Yeon-Sil Kim; Hong-Gyun Wu; Jin Ho Kim; Yong Chan Ahn; Dongryul Oh; Jong Hoon Lee
Journal:  Strahlenther Onkol       Date:  2016-03-14       Impact factor: 3.621

10.  Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.

Authors:  Hao Peng; Lei Chen; Yuan Zhang; Wen-Fei Li; Yan-Ping Mao; Fan Zhang; Rui Guo; Li-Zhi Liu; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  Oncologist       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.